High-dose-rate prostate brachytherapy: An excellent accelerated- hypofractionated treatment for favorable prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 5, 2010, Pages 481-488

  Martinez, Alvaro A ^a   Demanes, Jeffrey ^b   Vargas, Carlos ^a   Schour, Lionel ^b   Ghilezan, Michel ^a   Gustafson, Gary S ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b California Endocurietherapy Cancer Center   (United States)

Author keywords

Brachytherapy; High dose rate; Intensity modulated; Permanent seeds; Prostate cancer; Toxicity

Indexed keywords

PALLADIUM; IRIDIUM; RADIOISOTOPE;

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DYSURIA; FOLLOW UP; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION INJURY; URINARY FREQUENCY; URINARY URGENCY; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; INTENSITY MODULATED RADIATION THERAPY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSTATE TUMOR; RADIATION RESPONSE; SURVIVAL; TREATMENT OUTCOME;

AGED; BRACHYTHERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PALLADIUM; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOISOTOPES; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78049478731     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181b9cd2f     Document Type: Article

References (32)

1. Mettlin CJ, Murphy GP, McDonald CJ. The national Cancer Data Base Report on increase use of brachytherapy for the treatment of patients with prostate carcinoma in the USA. Cancer. 1999;86:1877-1882.
2. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141-2149.
3. Hanks GE, Hanlon AL, Pinover WH, et al. Survival advantage for prostate cancer patients treated with high-dose 3-dimensional conformal radiotherapy. Cancer J Sci Am. 1999;5:152-158.
4. Zelefsky M, Fuks Z, Wolfe T, et al. Locally advanced prostate cancer: long term toxicity outcome after 3-dimensional conformal radiation therapy-a dose escalation study. Radiology. 1998;209:169-174.
5. Blasko JC, Haakon R, Grimm P. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl. 1991;137:113.
6. Beyer DC, Priestley JB. Biochemical disease-free survival following I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 1997;37:559-563.
7. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys. 2001;49:61-69.
8. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy treatment reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171:1098-1104.
9. Demanes JD, Rodriguez R, Schour L, et al. High dose rate intensitymodulated radiotherapy with external beam radiotherapy for prostate cancer: California endocurietherapy 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306-1316.
10. Borghede G, Hendelin H, Holmang S, et al. Irradiation of localized prostatic carcinoma with a combination of high-dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland. Int J Radiat Oncol Biol Phys. 1997;47:245-250.
11. Galalae RM, Martinez AA, Mate T. Long-term outcome by risk factors using conformal High Dose Rate Brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1048-1055.
12. Zelefski M, Fuks Z, Hunt M. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J Radiat Oncol Biol Phys. 2002;53:1111-1116.
13. Martinez AA, Yan D, Lockman D. Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;50:1226-1234.
14. Edmundson GK, Rizzo NR, Teahan M. Concurrent treatment planning for outpatient high dose rate prostate template implants. Int J Radiat Oncol Biol Phys. 1993;27:1215.
15. Edmundson GK, Yan D, Martinez AA. Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;33:1257-1263.
16. Pollack A, Zagars G, Starkschall G. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105.
17. Martinez AA, Gonzalez J, Spencer W, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003;169: 974-980.
18. Demanes JD, Rodriguez RR, Altieri GA. High dose rate prostate brachytherapy: the California Endocurietherapy (CET) method. Radiother Oncol. 2000; 57:289-296.
19. Wallner K, Roy J, Harrison L, et al. Dosimetry guidelines to minimized urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. IntJ Radiat Oncol Biol Phys. 1995;32:465-471.
20. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. Oncology. 1999;17:517-522.
21. Gelbaum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:119.
22. Saputo K, Calcaterra A, Boyea G, et al. The impact of androgen deprivation on genito-urinary toxicity measured by the International Prostate Symptoms Score- Quality of life Questionnaire for prostate cancer patients undergoing different radiation treatment modalities. Int J Radiat Oncol Biol Phys. 2006;66(suppl):S545. Abstract 2601.
23. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys. 2001;51:213-214.
24. Yoshioka Y, Nose T, Yoshida K. High-dose-rate interstitial brachytherapy as monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 2000;48:675-681.
25. Brenner DJ, Martinez AA, Edmundson GK. Direct evidence that prostate tumors show a high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6-13.
26. Logue JP, Livsey JE, Cowan RA, et al. Hypofractionated conformal radiotherapy of prostate cancer: 5-year outcome analysis. Int J Radiat Oncol Biol Phys. 2002;54:189.
27. Yeoh E, Frasier RJ, McGowan R. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a phase iii randomized trial. Int. J Radiat Oncol Biol Phys. 2003;55:943-955.
28. Fowler JF, Ritter MA, Chappell R. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;56:1093-1104.
29. Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology. 1972;135-146.
30. Calcaterra AJ, Saputo K, Boyea G, et al. Assessment of quality of life of bowel function in prostate cancer patients undergoing different radiation treatment modalities with or without hormones. Int J Radiat Oncol Biol Phys. 2006;66(suppl):S133.Abstract 1006.
31. Hardy MM, Robertson JM, Calcaterra A, et al. A quality of life assessment of genito-urinary and sexual function of patients diagnosed with prostate cancer undergoing various radiation treatment modalities. Int J. Radiat Oncol Biol Phys. 2006;66(suppl):S371.Abstract 2289.
32. Zelefsky MJ, Hollister T, Raben A. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261-1266.